Portal Hypertension - Pipeline Review, H2 2016

Date: August 31, 2016
Pages: 69
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: PD7829F8C39EN
Leaflet:

Download PDF Leaflet

Portal Hypertension - Pipeline Review, H2 2016

SUMMARY

Global Markets Direct’s, ‘Portal Hypertension - Pipeline Review, H2 2016’, provides an overview of the Portal Hypertension pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Portal Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Portal Hypertension and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Portal Hypertension
  • The report reviews pipeline therapeutics for Portal Hypertension by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Portal Hypertension therapeutics and enlists all their major and minor projects
  • The report assesses Portal Hypertension therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Portal Hypertension
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Portal Hypertension
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Portal Hypertension pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Portal Hypertension Overview
Therapeutics Development
Pipeline Products for Portal Hypertension - Overview
Portal Hypertension - Therapeutics under Development by Companies
Portal Hypertension - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Portal Hypertension - Products under Development by Companies
Portal Hypertension - Companies Involved in Therapeutics Development
Conatus Pharmaceuticals Inc.
Cumberland Pharmaceuticals, Inc.
Galectin Therapeutics, Inc.
Genextra S.p.a.
LinXis B.V.
Mezzion Pharma Co. Ltd.
Portal Hypertension - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
emricasan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GRMD-02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ifetroban sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LIN-003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
obeticholic acid - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
udenafil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Portal Hypertension - Dormant Projects
Portal Hypertension - Discontinued Products
Portal Hypertension - Product Development Milestones
Featured News & Press Releases
Oct 20, 2015: Conatus Pharmaceuticals Announces Acceptance of Late-Breaking Abstract for AASLD Annual Meeting
ep 23, 2015: Conatus Announces Top-line Results From Multicenter Phase 2 Portal Hypertension Clinical Trial in Patients With Liver Cirrhosis
Nov 10, 2014: Conatus Pharmaceuticals Presents Late-Breaking Poster At AASLD Annual Meeting
Oct 08, 2014: Conatus Pharmaceuticals Announces Acceptance Of Late-Breaking Abstract For AASLD Annual Meeting
Sep 02, 2014: Conatus Pharmaceuticals Initiates Phase 2 Trial in Patients with Liver Cirrhosis and Separate Open Label Phase 2 Trial in Cirrhosis Patients with Portal Hypertension
Nov 08, 2012: Intercept Pharma To Present Phase IIa Portal Hypertension Data At AASLD's Annual Liver Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Portal Hypertension, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Portal Hypertension - Pipeline by Conatus Pharmaceuticals Inc., H2 2016
Portal Hypertension - Pipeline by Cumberland Pharmaceuticals, Inc., H2 2016
Portal Hypertension - Pipeline by Galectin Therapeutics, Inc., H2 2016
Portal Hypertension - Pipeline by Genextra S.p.a., H2 2016
Portal Hypertension - Pipeline by LinXis B.V., H2 2016
Portal Hypertension - Pipeline by Mezzion Pharma Co. Ltd., H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Portal Hypertension - Dormant Projects, H2 2016
Portal Hypertension - Discontinued Products, H2 2016

LIST OF FIGURES

Number of Products under Development for Portal Hypertension, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

COMPANIES MENTIONED

Conatus Pharmaceuticals Inc.
Cumberland Pharmaceuticals, Inc.
Galectin Therapeutics, Inc.
Genextra S.p.a.
LinXis B.V.
Mezzion Pharma Co. Ltd.
Skip to top


Hypertension - Pipeline Review, H2 2015 US$ 1,700.00 Dec, 2015 · 539 pages

Ask Your Question

Portal Hypertension - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: